what drug is semaglutide Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s Half of people stop taking

Clinical Evidence Supporting Combination Therapy Research published in diabetes and endocrinology journals consistently shows that GLP-1 agonists combined with metformin produce superior A1C reductions compared to monotherapy

The goal is not just short-term weight loss but sustainable metabolic health

Conclusion: Making Informed Decisions About Semaglutide Therapy Semaglutides side effect profile is well-characterized through extensive clinical trial data involving over 11,000 participants in the SUSTAIN and PIONEER programs, thousands more in the STEP weight management trials, and ongoing real-world surveillance

Standard safety monitoring